Adverum Biotechnologies (ADVM) announced Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical trial evaluating ADVM-022

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to Adverum Biotechnologies (ADVM) announced Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical trial evaluating ADVM-022

RBC Capital Downgrades Adverum Biotechnologies (ADVM) to Sector Perform

April 29, 2021 6:18 AM EDT

RBC Capital analyst Luca Issi downgraded Adverum Biotechnologies (NASDAQ: ADVM) from Outperform to Sector Perform with a price target of $6.00 (from $30.00).

The analyst comments "ADVM announced a serious adverse event of hypotony (decreased intraocular pressure), panuveitis and loss of vision in a DME... More